The Synergy of Innovation and Responsibility in Peptide Manufacturing

The pharmaceutical and biotechnology sectors are integrating sustainability into drug discovery, with the peptide industry adopting "Green Peptide Chemistry" to reduce environmental impact and enhance efficiency.

Life Sciences Review | Tuesday, May 05, 2026

The global pharmaceutical and biotechnology sectors are moving beyond mere regulatory compliance toward a holistic integration of sustainability into the very fabric of drug discovery and manufacturing. Within this broader transformation, the research peptide industry stands as a vanguard of innovation. Once characterized by chemically intensive processes and substantial solvent consumption, the sector is aggressively pivoting toward "Green Peptide Chemistry." This transition is not just an operational adjustment but a strategic realignment with global sustainability mandates, fundamentally altering how bioactive peptides are synthesized, purified, and delivered.

Conventionally, peptide synthesis—particularly Solid-Phase Peptide Synthesis (SPPS)—relied heavily on hazardous polar aprotic solvents such as N, N-dimethylformamide (DMF), dichloromethane (DCM), and N-methyl-2-pyrrolidone (NMP). These substances, while effective, pose significant environmental and health risks and contribute to a large carbon footprint due to the high volumes required for washing and deprotection steps.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

Manufacturers are increasingly adopting binary solvent systems, such as anisole combined with lesser amounts of greener polar components, or utilizing 2-methyltetrahydrofuran (2-MeTHF), a bio-derived solvent sourced from renewable agricultural byproducts. The industry is seeing a surge in the use of cyclopentyl methyl ether (CPME) and water-based surfactant technologies that enable lipophilic reactions in aqueous media.

Parallel to solvent replacement is the innovation in coupling reagents. Modern workflows prioritize reagents with high atom economy—maximizing the number of atoms from reactants that end up in the final product—thereby reducing byproduct formation. This "prevention at the source" approach is a cornerstone of green chemistry, ensuring that sustainability is designed into the synthesis protocol rather than managed as an afterthought.

Process Intensification and Energy Efficiency

Beyond chemical substitution, the physical methodology of peptide production has undergone a revolution aimed at drastic energy reduction. Traditional batch manufacturing is energy-intensive, often requiring prolonged heating and cooling cycles. The industry’s response has been the widespread adoption of flow chemistry and continuous manufacturing principles.

In flow chemistry, reactions occur in a continuously flowing stream rather than in static batches. This method significantly enhances heat and mass transfer, allowing reactions to proceed faster and with higher yields. The precise control offered by flow systems reduces thermal energy requirements and minimizes the need for excess reagents. Consequently, the manufacturing footprint shrinks, both physically and environmentally.

Another major stride is the optimization of downstream processing. Lyophilization (freeze-drying) has long been the industry standard for peptide isolation, yet it is energy-inefficient. Current trends indicate a shift toward alternative isolation techniques, such as spray drying and precipitation-crystallization. These methods not only consume a fraction of the energy but also allow for better control over particle engineering, which is crucial for the bioavailability of the final research product.

The Circular Economy in Peptide Synthesis

Waste management in peptide manufacturing is evolving from a linear "dispose" model to a circular "recover and repurpose" framework. Given that solvents can account for up to 90 per cent of the mass in peptide synthesis, their recovery is a high-priority sustainability target. Advanced distillation and membrane filtration technologies are now integral to modern facilities, enabling on-site solvent recycling with purity levels sufficient for re-use in subsequent wash cycles.

The industry is rethinking the solid supports used in SPPS. The development of biodegradable resins and the implementation of "atom-efficient" linkers ensure that the solid waste generated is less persistent in the environment. Innovations in membrane-enhanced peptide synthesis (MEPS) enable the separation of unreacted reagents from the growing peptide chain, allowing the recycling of valuable amino acids and coupling agents that would otherwise be discarded. This circular approach significantly reduces the E-factor (environmental factor) of production, a metric that measures the ratio of waste to product.

Ethical Supply Chains and Logistics

Sustainability extends beyond the laboratory walls to the global supply chain. Manufacturers are increasingly scrutinizing their upstream partners, prioritizing raw material suppliers who adhere to ethical labor practices and environmental stewardship. This includes sourcing amino acids produced via fermentation from renewable feedstocks rather than petrochemical routes.

Logistically, the industry is embracing "green distribution." This involves optimizing cold-chain storage to reduce energy consumption during transport and utilizing packaging materials derived from recycled or compostable sources. There is also a strategic trend toward near-shoring manufacturing capabilities. By locating production facilities closer to key research hubs, companies are drastically reducing the scope three emissions associated with global freight, ensuring that the carbon cost of delivering a peptide is as low as possible.

The research peptide industry’s collective initiatives reflect a strong and intentional alignment with the United Nations Sustainable Development Goals (SDGs). By advancing more efficient, cost-effective peptide synthesis, the sector supports SDG 3: Good Health and Well-being, enabling faster progress in developing therapeutics for metabolic disorders, oncology, and antimicrobial resistance. Its embrace of flow chemistry, automation, and digital technologies reinforces SDG 9: Industry, Innovation, and Infrastructure, driving modernization and enhancing industrial resilience. In parallel, the industry’s commitment to solvent recycling, green chemistry alternatives, and circular waste practices directly advances SDG 12: Responsible Consumption and Production, promoting safer chemical management and meaningful waste reduction. Additionally, ongoing efforts to lower energy use in manufacturing and to reduce carbon-intensive logistics support SDG 13: Climate Action, contributing to broader global initiatives to mitigate climate change.

No longer content with reactive compliance, the sector is embedding sustainability into the DNA of its operations. Through the convergence of green chemistry, process intensification, and circular economic models, manufacturers are proving that high-quality scientific output and environmental stewardship are not mutually exclusive—they are synergistic. As these technologies mature and scale, the industry is poised to serve as a global benchmark for sustainable pharmaceutical science, driving progress toward a healthier planet and a healthier population.

More in News

Choosing Microbial CDMO without Losing Process Control

Commercial biologics programs rarely stall because a sponsor failed to reserve manufacturing capacity. Delays are more likely to appear when fermentation assumptions, purification readiness, assay design and batch documentation fall out of sync. Microbial manufacturing is particularly sensitive at this stage. A process that performs well during development can quickly lose momentum if harvest conditions are not fully understood or impurity clearance has not been aligned with the characteristics of the molecule. For executives evaluating a CDMO, manufacturing capacity is important, but maintaining process continuity is even more critical. The strongest CDMOs do not treat development and manufacturing as separate stages handed from one department to another. Instead, they manage them as a continuous, controlled process. Analytical strategy is developed while the process is still being refined, manufacturing constraints are identified before GMP transfer, sampling routes are planned early and documentation evolves alongside the program instead of being rebuilt for clinical or commercial manufacturing. This goes beyond administrative efficiency. It is an important part of controlling risk. Changes to analytical methods or batch records late in development can trigger comparability work and make regulatory review more challenging. "Richter BioLogics aligns well with the priorities many sponsors look for when they need microbial expertise backed by GMP manufacturing." A thorough evaluation should also examine how fermentation and purification work together in practice. Separate upstream and downstream suites can offer sponsors greater flexibility, but only if the transition between them is carefully managed. Having real-time harvest data, purification teams ready to receive material, buffers prepared in advance and clear sample routes in place helps avoid the disruption that often occurs between the bioreactor and the first chromatography step. The same level of scrutiny applies to plasmid DNA manufacturing, where supercoiled content, host-cell impurities, endotoxin burden and unwanted isoforms all influence whether the final material is suitable for its intended use. Quality systems should be assessed through evidence, not broad assurances. Every GMP manufacturing program generates extensive documentation, and that record should remain clear and consistent from raw material receipt and media preparation through in-process testing, deviations, investigations and final product release. Buyers should look at whether quality control is integrated closely enough with manufacturing to detect early process signals. They should also consider whether the CDMO has the in-house analytical expertise needed for release testing, stability studies, troubleshooting and comparability work, instead of relying on outside laboratories whenever challenges arise. "For sponsors working to demanding timelines, Richter BioLogics brings together specialized microbial expertise, disciplined documentation, in-house analytical testing and direct project coordination." Scale also deserves careful consideration. A larger facility does not automatically make decisions faster, and a smaller specialist may not have enough built-in redundancy. A better question is whether the manufacturing model gives sponsors direct access to scientific expertise while providing the GMP infrastructure needed to support late-stage development and commercial production. That balance is especially important in microbial biologics. Therapeutic proteins, antibody fragments, bacterial vaccines and plasmid DNA each bring different manufacturing demands, so buyers should look beyond broad claims about capacity and examine the depth of process and analytical expertise behind them. Richter BioLogics aligns well with the priorities many sponsors look for when they need microbial expertise backed by GMP manufacturing. Its capabilities span process development, analytical development, microbial GMP manufacturing and plasmid DNA production, including the pART plasmid platform. The company operates independent upstream and downstream processing lines across two multiproduct GMP facilities, with quality control integrated throughout manufacturing campaigns. It supports therapeutic proteins, VHH or Nanobody formats, bacterial vaccines and plasmid DNA. A long GMP manufacturing track record, recent capacity expansion, in-house analytical capabilities and a 2026 FDA inspection with zero observations provide added confidence. For sponsors working to demanding timelines, Richter BioLogics brings together specialized microbial expertise, disciplined documentation, in-house analytical testing and direct project coordination. ...Read more

Inventus welcomes senior figure from Google as a board adviser

Inventus, the only company in the world dedicated to creating purpose-built devices and technology solutions exclusively for clinical trials, has made a key appointment from Google to its advisory board. Mark Bennett, a Vice President at Google, will be working with Inventus in the capacity of Board Adviser. Bennett has more than two decades in senior leadership roles at companies including Microsoft, Sainsbury’s & Tesco. He is currently Google’s Vice President of Knowledge & Information Partnerships for the EMEA region, leading product partnerships for Search, Gemini, Maps, Commerce, Research and Ads . Bennett has spent more than 10 years in Google Partnerships across a range of teams including Knowledge & Information, Android, Google Hardware and Google Play. Bennett’s previous roles at Google include VP for Platforms and Devices Partnerships for the APAC region and Vice President for Google’s Global Android Partnerships. Bennett said he was excited to support Inventus - known for its innovative and industry leading clinical trial solutions - to help map out its next phase of growth. He said: “I’m delighted to be advising the board at Inventus. I’m impressed by the growth and strategy of the company and am looking forward to helping them accelerate that trajectory. I’ve been intrigued by the biomedical sciences sector for some time and seen how AI is an increasingly important factor for the industry. I’ll be advising Inventus on how technology can be harnessed to enhance the efficiency, effectiveness and overall impact of clinical trials, helping bring better treatments to patients faster.” Bennett is the second key appointment from Google at Inventus in recent months. Earlier this year, Jon French, Managing Director of Google’s Android Global Business, was appointed Group Managing Director at Inventus. Commenting on Bennett’s new role, French said: “I could not be more excited to welcome Mark to the Inventus advisory board. I know personally what an incredible leader Mark is. His expertise and perspective will be tremendous assets to our business. “As Inventus enters its next phase of growth, his experience, judgement and strategic vision will help shape our direction and strengthen our ability to achieve our long-term ambitions. At the heart of everything we do at Inventus is a commitment to help bring life-changing treatments to patients faster.” Bennett is the second appointment to the Inventus advisory board – he joins Stacy Hurt, chief patient officer at Parexel, who was welcomed as a Board Adviser in the summer. Parexel is a global clinical development partner. Hurt leads efforts to integrate patient perspectives into drug development and healthcare at their earliest stages. Hurt has more than two decades of leadership experience in the pharmaceutical space. She has worked for GlaxoSmithKline, Transdermal Therapeutics and Colon Cancer Coalition across sales, training and development and has over a decade of experience in patient advocacy. Steve Sanghera, CEO and Co-Founder of Inventus, said: “I am delighted to announce the exceptional appointment of Mark Bennett to the Inventus Board. Mark brings world class technology leadership and knowledge which will be instrumental in guiding our journey as we navigate how AI will shape and influence clinical trials. Mark’s appointment reflects the continuous growth of Inventus within the industry. Together with Stacy, the expertise that we now have at Inventus also demonstrates our commitment to building a business that focuses on technological excellence and the patients which sit at the heart of a clinical trial.” ...Read more

Growing Concerns About Data Continuity in Biopharma Evidence Generation

One of the common concerns within biopharma is not a matter of generating evidence per se. What makes it even harder is the possibility of sustaining a consistent stream of information through several studies or regulations over prolonged periods of time. As such, the issue of data continuity gains more importance as evidence generation software solutions are currently evaluated by potential buyers. Evidentiary initiatives are never limited to the sole scope of their objectives. Information retrieved once can become relevant several times over the life cycle of a particular product. Researchers may need to re-examine certain findings, compare results of treatment between different periods of time or study data acquired within separate research processes. It becomes especially complicated if there are no consistent information sources within an organization. Such considerations begin to impact the choice of evidence generation software. While the tools themselves are hardly ever used to produce any scientific insights directly, their contribution lies in facilitating further evidence processing and management. The problem becomes apparent as evidentiary research programs move past their initial objectives. It is rare for evidence generation initiatives to have a definite deadline or goal. Several years may pass between the start of the research process and its end, which means that there can be many staff changes, reconsiderations of previous assumptions or emergence of new questions. When information proves hard to find or analyze, the whole process can be slowed down significantly. The amount of effort spent tracking documents, verifying the integrity of information and understanding research history may prove to be considerable. At the same time, these aspects might not become a major focus of technology evaluation. Procurement conversations about evidence generation software solutions are shifting in this direction. Buyers' attention moves from operational effectiveness to information sustainability as evidence programs grow more extensive and complex. They are starting to see evidence generation software platforms as tools for sustaining knowledge over time rather than project management resources. This brings a change to the list of priorities for software developers. Features aimed at optimizing research processes are essential but buyers become concerned with data preservation as well. As such, information continuity becomes part of a solution's institutional memory function rather than just another aspect of project management. While data continuity may not be as prominent as some new trends in evidence analytics, it addresses a pressing problem faced by many biopharma teams. Evidence generation projects tend to outlast their budgets, original objectives or even the members of a team conducting research. For biopharma companies investing in such tools, the problem is shifting from acquiring new information to keeping existing data context-sensitive. ...Read more

Inventus welcomes senior figure from Google as a board adviser

Specials

The Synergy of Innovation and Responsibility in Peptide Manufacturing

The pharmaceutical and biotechnology sectors are integrating sustainability into drug discovery, with the peptide industry adopting "Green Peptide Chemistry" to reduce environmental impact and enhance efficiency.